NB-360

• UNSPSC Description:

  NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E[1][2].

• Target Antigen:

  Beta-secretase

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/nb-360.html

• Purity:

  99.22

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=NC=C(C#N)C=C1C)NC2=CC=C(F)C([C@]3(C)CO[C@](C(F)(F)F)(C)C(N)=N3)=C2

• Molecular Weight:

  449.40

• References & Citations:

  [1]Neumann U, et al. Mol Neurodegener. 2015 Sep 3;10:44. doi: 10.1186/s13024-015-0033-8.|[2]Neumann U, et al. The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects. Br J Pharmacol. 2019 Sep;176(18):3435-3446.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1262857-73-7